Citigroup’s Beam Therapeutics BEAM Stock Holding History

Citigroup’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-30,000	Closed	-$510K	–	6089
2025 Q2	$510K	Buy	+30,000	New	+$522K	﹤0.01%	3614
2024 Q3	–	Sell	-25,000	Closed	-$586K	–	5683
2024 Q2	$586K	Sell	25,000 -24,900	-50%	-$612K	﹤0.01%	3287
2024 Q1	$1.65M	Buy	49,900 +25,000	+100%	+$779K	﹤0.01%	2594
2023 Q4	$678K	Buy	+24,900	New	+$619K	﹤0.01%	3169
2023 Q3	–	Sell	-17,500	Closed	-$559K	–	5670
2023 Q2	$559K	Hold	17,500	–	–	﹤0.01%	3300
2023 Q1	$536K	Buy	17,500 +1,600	+10%	+$63.1K	﹤0.01%	3085
2022 Q4	$622K	Buy	+15,900	New	+$712K	﹤0.01%	3008

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Citigroup's BEAM Position: Q2 2026 in Review

Citigroup increased its Beam Therapeutics (BEAM) stake by 108% in Q2 2026, buying an estimated $2.17M and bringing the position to 138,866 shares worth $4.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2184.

Citigroup first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $8.56M in Q1 2024. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Citigroup held 138,866 shares of Beam Therapeutics worth $4.77M as of Q2 2026.
Citigroup bought 72,008 Beam Therapeutics shares in Q2 2026, an estimated $2.17M.
Beam Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2184 holding.
Citigroup first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
Citigroup's Beam Therapeutics position peaked at $8.56M in Q1 2024.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.